RxDoctor Payments Data

Sarah Tarplin, MD

Rheumatology · Savannah, GANPI 1639559594

Payments from drug & device makers

$8,910in general payments, 2019–2025

Across 393 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$2K
  • Johnson & Johnson$1K
  • UCB, Inc.$508
  • Novartis$407
  • E.r. Squibb & Sons, L.L.C.$394
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$8,79299%
  • Education$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,910 in reported general payments places this provider in the 55th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$769,613
Medicare patients
263
Services billed
47,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept94$707,548
Humira(Cf) PenAdalimumab56$572,845
OtezlaApremilast31$169,426
Orencia ClickjectAbatacept28$155,196
Actemra ActpenTocilizumab21$69,409
Hydroxychloroquine Sulfate380$15,625
Leflunomide130$6,304
MethotrexateMethotrexate Sodium203$4,757
Mycophenolate Mofetil27$3,781
Duloxetine Hcl69$1,687
Cevimeline Hcl13$1,663
Prednisone208$1,536
Celecoxib31$1,158
Diclofenac Sodium24$625
Gabapentin52$607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$2,178$169,42631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →